Vima Therapeutics is a clinical-stage biotechnology company pioneering a new era in the treatment of dystonia and related movement disorders.
We are advancing VIM0423, a potential first-in-class oral therapy for dystonia, with the goal of helping individuals regain control of their movements by targeting the underlying cause of the disease.
Vima brings together a team of physicians, scientists, and drug developers with deep expertise in movement disorders and a shared commitment to deliver a meaningful oral therapy for patients.
Company Details
- Employees
- 13
- Address
- The Root Brain Causes. Vima Therapeutics Is Testing An Experimental Oral Medicine Going After Muscarinic Cholinergic Receptors.
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.vimatx.com
Vima Therapeutics Questions
Vima Therapeutics's website is http://www.vimatx.com
Vima Therapeutics's LinkedIn profile is https://www.linkedin.com/company/vima-therapeutics
Vima Therapeutics has
13 employees.
View email and phone details for 13
employees at Vima Therapeutics.
Vima Therapeutics's industry is
Biotechnology Research
Vima Therapeutics's top competitors are
Chalk,
Keros Therapeutics,
Cold Start Therapeutics,
Proteinqure,
Ausperbio,
Syndeio Biosciences,
Vivodyne,
Atlas Venture,
Antares Therapeutics,
Gc Ai.
Vima Therapeutics's categories are Biotechnology Research
